Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STDS - Short Term Target of $8.75 -- Ignore unavailable to you. Want to Upgrade?

To: Todd Frank who wrote (11)	5/4/1998 4:51:00 PM
From: Andre Daedone	Respond to of 15

Todd: I never bought STDS. They never answered my questions so I placed my money in another investment. Good luck to you. Andr‚

To: Todd Frank who wrote (11)	5/5/1998 4:19:00 PM
From: Andre Daedone	Read Replies (1) \| Respond to of 15

Todd: Too late for me but the company finally got their head out of the sand and answered my email. Here it is: 1. The 1995 and 1996 audit is complete (in draft form) and shall be available within the next few weeks. The 1997 audit is schedule to be complete in the next few weeks as well. 2. 1997 Approximate: Sales: $13 million, Net: $880,000 3. Protein Research does not manufacture protein specifically, they represent a lot of different companies like ourselves. We don't know if they have a specific designer whey in process, however we are currently working on a sports nutrition line ourselves. The way I see it, is that their EPS will be about .06 cents. This will give them a P/E of 75 @ 4.50 a share. It really depends on their projected growth rate to determine an optimum share price. Good luck. Andr‚